Arrowhead Pharmaceuticals (MEX:ARWR) Cyclically Adjusted Book per Share: MXN24.87 (As of Mar. 2026)


MEX:ARWR Arrowhead Pharmaceuticals Inc MEX:ARWR
49 GF Score
Price MXN454.55
GF Value MXN293.33
! 7 Warning Signs
View Full Analysis

What is Arrowhead Pharmaceuticals Cyclically Adjusted Book per Share?

Arrowhead Pharmaceuticals MEX:ARWR 49 Cyclically Adjusted Book per Share is MXN24.87 as of Mar. 2026. GuruFocus rates MEX:ARWR with a GF Score™ of 49/100 and a GF Value™ of MXN293.33. The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Arrowhead Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was MXN78.762. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is MXN24.87 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Arrowhead Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 8.50% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 4.10% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 9.60% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 3.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Arrowhead Pharmaceuticals was 62.60% per year. The lowest was -38.70% per year. And the median was 4.10% per year.

As of today (2026-07-02), Arrowhead Pharmaceuticals's current stock price is MXN454.55. Arrowhead Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was MXN24.87. Arrowhead Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 18.28.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Arrowhead Pharmaceuticals was 43.20. The lowest was 0.47. And the median was 11.01.


Arrowhead Pharmaceuticals  (MEX:ARWR) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Arrowhead Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=454.55/24.87
=18.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Arrowhead Pharmaceuticals was 43.20. The lowest was 0.47. And the median was 11.01.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Arrowhead Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Arrowhead Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Arrowhead Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arrowhead Pharmaceuticals Cyclically Adjusted Book per Share Chart

Arrowhead Pharmaceuticals Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 48.45 122.33 70.88 95.60 42.96

Arrowhead Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 112.75 92.35 42.96 22.59 24.87

MEX:ARWR vs CYTK, TECH, KRYS: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Arrowhead Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arrowhead Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arrowhead Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Arrowhead Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


MEX:ARWR
49GF Score
Arrowhead Pharmaceuticals Inc MEX:ARWR
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arrowhead Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Arrowhead Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=78.762/330.2130*330.2130
=78.762

Current CPI (Mar. 2026) = 330.2130.

Arrowhead Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 18.356 241.018 25.149
201609 26.497 241.428 36.241
201612 27.087 241.432 37.048
201703 23.644 243.801 32.024
201706 21.781 244.955 29.362
201709 19.759 246.819 26.435
201712 18.548 246.524 24.845
201803 23.707 249.554 31.369
201806 22.884 251.989 29.988
201809 20.246 252.439 26.484
201812 36.486 251.233 47.956
201903 41.227 254.202 53.555
201906 45.643 256.143 58.842
201909 50.559 256.759 65.023
201912 93.279 256.974 119.864
202003 113.871 258.115 145.678
202006 111.321 257.797 142.591
202009 99.644 260.280 126.417
202012 87.605 260.474 111.060
202103 87.555 264.877 109.152
202106 83.455 271.696 101.429
202109 80.575 274.310 96.996
202112 72.928 278.802 86.376
202203 85.193 287.504 97.849
202206 86.319 296.311 96.195
202209 75.653 296.808 84.168
202212 69.255 296.797 77.052
202303 75.355 301.836 82.439
202306 58.399 305.109 63.204
202309 44.044 307.789 47.253
202312 25.328 306.746 27.266
202403 64.682 312.332 68.385
202406 48.747 314.175 51.235
202409 29.358 315.301 30.746
202412 8.734 315.605 9.138
202503 101.255 319.799 104.552
202506 71.192 322.561 72.881
202509 63.001 324.800 64.051
202512 74.494 324.054 75.910
202603 78.762 330.213 78.762

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of MXN24.87 mean?
Arrowhead Pharmaceuticals (MEX:ARWR) has a Cyclically Adjusted Book per Share of MXN24.87 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Arrowhead Pharmaceuticals and its competitors.
Is Arrowhead Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Arrowhead Pharmaceuticals' current Cyclically Adjusted Book per Share is MXN24.87. Overall, Arrowhead Pharmaceuticals has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Arrowhead Pharmaceuticals' Cyclically Adjusted Book per Share compare to CYTK and TECH?
Arrowhead Pharmaceuticals' Cyclically Adjusted Book per Share of MXN24.87 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Arrowhead Pharmaceuticals and its competitors. Arrowhead Pharmaceuticals's current Cyclically Adjusted Book per Share is MXN24.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arrowhead Pharmaceuticals stock overvalued right now?
Arrowhead Pharmaceuticals (MEX:ARWR) has a current Cyclically Adjusted Book per Share of MXN24.87. The stock's GF Value™ is MXN293.33, compared to a current price of MXN454.55 — trading 55% above its estimated fair value. The current Cyclically Adjusted Book per Share is MXN24.87. Arrowhead Pharmaceuticals' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Arrowhead Pharmaceuticals (MEX:ARWR), the current Cyclically Adjusted Book per Share is MXN24.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arrowhead Pharmaceuticals (MEX:ARWR) Overvalued in 2026?

Based on GuruFocus' analysis, Arrowhead Pharmaceuticals stock appears to be overvalued. The current stock price of MXN454.55 is trading 55% above its estimated GF Value™ of MXN293.33.

Key valuation signals for MEX:ARWR:

  • Cyclically Adjusted Book per Share: MXN24.87
  • GF Value™: MXN293.33 vs. price of MXN454.55 (55% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the MEX:ARWR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Arrowhead Pharmaceuticals Business Description

Address 177 E Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
49GF Score

Get the complete analysis for MEX:ARWR

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN454.55
Price
MXN293.33
GF Value